Clinical laboratory
S. 866, the American Innovation and Jobs Act, and H.R. 2673, the American Innovation and R & D Competitiveness Act, provisions relating to immediate deductibility of research and development expenses under Internal Revenue Code Section 174. Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), and Section 502 of H.R. 6363, the Further Continuing Appropriations and Other Extensions Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2024 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests; H.R. 3248, the Diagnostic Lab Testing Transparency Act, Section 101 of H.R. 4822, the Health Care Price Transparency Act, Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, Section 105 of H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act, and Section 3 of S. 3548, the Health Care Price Transparency Act 2.0, provisions relating to publication of rates for laboratory services; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.
TAX - Taxation/Internal Revenue Code HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
KELLEY DRYE & WARREN LLP
3050 K STREET, NW, SUITE 400, WASHINGTON, DC, 20007, US
MAGGIE CLARKE CROSSWY DANA SCHNEEBERGER WOOD SCOTT MCGEE MAGGIE CLARKE CROSSWY SCOTT MCGEE DANA SCHNEEBERGER WOOD